Targeted Near-Infrared Fluorescence Imaging of Atherosclerosis: Clinical and Intracoronary Evaluation of Indocyanine Green.

ABSTRACT:

Objectives

This study sought to determine whether indocyanine green (ICG)-enhanced near-infrared fluorescence (NIRF) imaging can illuminate high-risk histologic plaque features of human carotid atherosclerosis, and in coronary atheroma of living swine, using intravascular NIRF-optical coherence tomography (OCT) imaging.

Background

New translatable imaging approaches are needed to identify high-risk biological signatures of atheroma. ICG is a U.S. Food and Drug Administration-approved NIRF imaging agent that experimentally targets plaque macrophages and lipid in areas of enhanced endothelial permeability. However, it is unknown whether ICG can target atheroma in patients.

Methods

Eight patients were enrolled in the BRIGHT-CEA (Indocyanine Green Fluorescence Uptake in H

SUBMITTER: Verjans JW 

PROVIDER: S-EPMC5136528 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature